Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial - Takeaways - MDSpire

Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial

  • By

  • Wei Xie

  • Lin-Jie Zhang

  • Chunxian Yue

  • Baojie Wang

  • Shougang Guo

  • Xuegan Lian

  • Chao Zhang

  • May 29, 2026

  • 0 min

Share

  • 1

    The RADIA study evaluates the safety and efficacy of B-cell depleting agents combined with daratumumab for severe autoimmune encephalitis.

  • 2

    This multicenter trial involves 200 patients with NMDA receptor encephalitis, randomized into three treatment groups.

  • 3

    The primary outcome is the proportion of patients achieving an mRS score ≤ 2 at 16 weeks post-treatment initiation.

  • 4

    Secondary outcomes include neurocognitive function, ICU stay duration, and adverse event monitoring over 48 weeks.

  • 5

    The study aims to provide high-quality evidence for new treatment options in patients with severe NMDA receptor encephalitis.

Original Source(s)

Safety and efficacy of combined B-cell depleting therapy and daratumumab in patients with autoimmune encephalitis (RADIA): study protocol for a multicenter, randomized trial

  • by Wei Xie, Lin-Jie Zhang, Chunxian Yue, Baojie Wang, Shougang Guo, Xuegan Lian, Chao Zhang

  • May 29, 2026

Related Content

Gray matter volume alterations in adolescents with ADHD are associated with cell type-specific transcriptional signatures

Remote ischemic preconditioning in elderly patients with acute myocardial infarction and transient ischemic attack: a retrospective cohort study

Kappa free light chain index in multiple sclerosis and other inflammatory CNS diseases: a pilot single-center study from Argentina